Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model

Nadja Zöller(Goethe University Frankfurt), August Bernd(Goethe University Frankfurt), Andrea Sättler, Stefan Kippenberger(Goethe University Frankfurt), Roland Kaufmann(Robert Koch Institute), Jürgen Bereiter‐Hahn(Goethe University Frankfurt), Martina Spiegel, Karsten Mewes, Diamant Thaçi(University of Lübeck), Maike Schultz(Goethe University Frankfurt)

Toxicology in Vitro

December 18, 2007

10.1016/j.tiv.2007.11.022

Cited by 64

Related Papers

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

|New England Journal of Medicine|2014|1.4k

Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines

|European Journal of Cancer|2019|589

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

|The Lancet|2015|569

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538

Biology of the Integument

|Unknown|1984|413